<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82371">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01983748</url>
  </required_header>
  <id_info>
    <org_study_id>DERMA-ER-DC 08</org_study_id>
    <nct_id>NCT01983748</nct_id>
  </id_info>
  <brief_title>Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma</brief_title>
  <official_title>A NON-COMMERCIAL, MULTICENTER, RANDOMIZED, TWO-ARMED, OPEN-LABEL PHASE III STUDY TO EVALUATE THE ADJUVANT VACCINATION WITH TUMOR RNA-LOADED AUTOLOGOUS DENDRITIC CELLS VERSUS OBSERVATION OF PATIENTS WITH RESECTED MONOSOMY 3 UVEAL MELANOMA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Erlangen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital L端beck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Homburg/Saar</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Erlangen</source>
  <oversight_info>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients suffering from uveal melanoma (typed positive for monosomy 3) will be vaccinated
      over a period of 2 years with Dendritic Cell loaded with autologous Tumor RNA.

      200 patients will be included. The Trial is an open multicenter Phase III Trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial arm A (DCaT-RNA) = Experimental intervention: Patients in arm A receive 8 vaccinations
      over a period of 2 years consisting of autologous, mature, monocyte-derived Dendritic Cells
      loaded with autologous tumor RNA (20 mio DC per vaccination); cells are given via
      intravenous infusions; vaccinations are followed by a 1 year observation (staging every 3
      months)

      Trial arm B (Observation) = Control: Patients in arm B receive standard care (observation
      only with staging every 3 months)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Prolongation of disease free survival</measure>
    <time_frame>Clinical staging every 3 months from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Skin, lymph node and ophtalmological inspection , medical history, laboratory, and abdominal sonography will be performed every 3 months, chest x ray will be  performed every 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prolongation of Overall survival</measure>
    <time_frame>Assessment every 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment for induction of immune responses</measure>
    <time_frame>The induction of immune responses will be researched in selected patients (in a minimum of 15 survivors per trial arm) 2 years after randomization.</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Uveal Melanoma, Monosomy 3 Positive, no Evidence for Metastases.</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Biological/Vaccine; Autologous Dendritic Cells loaded with autologous Tumor RNA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control, Standard of care, which is clinical control every 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous Dendritic Cells loaded with autologous Tumor RNA</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must suffer from melanoma of the uvea (stage T2, T3 and T4 [AJCC TNM grading
             2009]).

          -  Uveal melanoma must be resected and display a monosomy for chromosome 3 (will be
             determined by a validated qualitative analysis of loss of heterozygosity). Tumor
             material has to be stored appropriately in RNAlater solution for RNA preparation.

          -  The patient has to be free of detectable tumor at the time point of study enrollment
             (adjuvant setting), as assessed by clinical inspection, abdominal sonography, chest
             X-ray and evaluation of the tumor-marker S-100..

          -  Patients must have a WHO performance status of 0, 1 or 2 and must be in stable
             medical condition.

          -  Patients must be between 18 and 75 years old and must be able and willing to give
             informed consent.

          -  Women of child-bearing age must have a negative pregnancy test, and must oblige to
             use effective contraception until at least 4 weeks after the last vaccination.

          -  Patients must be willing to get hospitalized for at least 4 hours following
             vaccination(s), and to cooperate for the whole period of the trial.

          -  Patients must have fully recovered from surgery.

          -  Signed informed consent

        Exclusion Criteria:

          -  Any other major serious illness [e.g. active systemic infections, immunodeficiency
             disease, clinically significant heart disease, respiratory disease, bleeding
             disorders, cancer etc.] or a contraindication to leukapheresis.

          -  Evidence for HIV-1, HIV -2, HTLV-1, HBV, or HCV infection.

          -  Active autoimmune disease (such as but not limited to Lupus erythematosus, autoimmune
             thyroiditis or uveitis, multiple sclerosis, inflammatory bowel disease). Vitiligo and
             pathological laboratory results (autoantibodies) without clinical symptoms are,
             however, not an exclusion criterion.

          -  Previous splenectomy or radiation therapy to the spleen.

          -  Patients with organ allografts.

          -  Concomitant treatment with chemotherapy, immunotherapy, any investigational drug and
             paramedical substances. Patients may receive concomitant medications to control
             symptoms such as analgetics, antihypertensive medication, etc.

          -  History of other active malignant neoplasm within the preceding 5 years (excluding
             non-melanoma skin cancer or carcinoma in situ of the cervix).

          -  Organic brain syndrome or significant psychiatric abnormality which would impede
             informed consent and / or AND preclude participation in the full protocol and follow
             up.

          -  Positive pregnancy test / Pregnancy or lactation. If pregnancy occurs during the
             course of the trial to female patients in arm A or B, the patient has to be excluded.

          -  Detection of metastases. If uveal melanoma metastases  appear during the course of
             the trial, the patient has to be excluded.

          -  Lack of compliance of the patient.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerold Schuler, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Erlangen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Schuler-Thurner Beatrice, MD</last_name>
    <phone>0049 9131 85</phone>
    <phone_ext>45833</phone_ext>
    <email>beatrice.schuler-thurner@uk-erlangen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Schuler Gerold, Prof.</last_name>
    <phone>0049 9131 85</phone>
    <phone_ext>33661</phone_ext>
    <email>gerold.schuler@uk-erlangen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Department of Ophtalmology</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leonhard Holbach, Prof.</last_name>
      <phone>0039 9131 85</phone>
      <phone_ext>44728</phone_ext>
      <email>leonhard.holbach@uk-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Friedrich Kruse, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept. of Dermatology, University Hospital</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>90154</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Beatrice Schuler-Thurner, Associate Professor</last_name>
      <phone>0049 9131 85</phone>
      <phone_ext>33724</phone_ext>
      <email>beatrice.schuler-thurner@uk-erlangen.de</email>
    </contact>
    <contact_backup>
      <last_name>Stina Rosenheinrich, Study nurse</last_name>
      <phone>0049 9131 85</phone>
      <phone_ext>45849</phone_ext>
      <email>stina.rosenheinrich@uk-erlangen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Gerold Schuler, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Department of Ophtalmology</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annemarie Klingenstein, MD</last_name>
      <phone>0049 89 5160</phone>
      <phone_ext>3801</phone_ext>
      <email>annemarie.klingenstein@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Anselm Kampik, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Department of Ophtalmology</name>
      <address>
        <city>W端rzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>T. Meyer Ter-Wehn, MD</last_name>
      <phone>0049 931 201</phone>
      <phone_ext>206 28</phone_ext>
      <email>meyer_t3@augenklinik.uni-wuerzburg.de</email>
    </contact>
    <investigator>
      <last_name>Franz Grehn, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Department of Ophtalmology</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Metz, MD</last_name>
      <phone>0049 201 7238</phone>
      <phone_ext>3471</phone_ext>
      <email>Claudia.Metz@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Norbert Bornfeld, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Department of Ophtalmology</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Marie Conigliari, Study nurse</last_name>
      <phone>0049 6841 16</phone>
      <phone_ext>22387</phone_ext>
      <email>Augenklinik.studienarzt@uks.eu</email>
    </contact>
    <investigator>
      <last_name>Berthold Seitz, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Department of Ophtalmology</name>
      <address>
        <city>L端beck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julia Lueke, MD</last_name>
      <phone>0049 451 500 22</phone>
      <phone_ext>11</phone_ext>
      <email>Julia.Lueke@uk-sh.de</email>
    </contact>
    <investigator>
      <last_name>Salvatore Grisanti, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Department of Ophtalmology</name>
      <address>
        <city>T端bingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ulrike Hagemann, Study nurse</last_name>
      <phone>0049 7071 29837</phone>
      <phone_ext>30</phone_ext>
      <email>ulrike.hagemann@med.uni-tuebingen.de</email>
    </contact>
    <investigator>
      <last_name>Ulrich Bartz-Schmidt, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 7, 2013</lastchanged_date>
  <firstreceived_date>September 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Erlangen</investigator_affiliation>
    <investigator_full_name>PD Dr. med. univ. Beatrice Schuler-Thurner</investigator_full_name>
    <investigator_title>Coordinating Investigator</investigator_title>
  </responsible_party>
  <keyword>Uveal Melanoma, Monosomy 3</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Monosomy</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
